ETF overview
The Virtus Biotech ETF seeks to replicate the overall financial performance, encompassing both price appreciation and income generation, of the LifeSci Biotechnology Products Index, prior to any deductions for fees and expenses. This index specifically comprises biotechnology companies that have received approval from the FDA for at least one drug therapy. Furthermore, the fund underwent a name change on February 27, transitioning from Virtus LifeSci Biotech Products ETF to its current designation.
Fund facts
- Expense ratio
- 0.34%
- Fund assets
- 132.14M USD (all share classes)
- Issuer
- Virtus
- Inception date
- Dec 16, 2014
- Number of holdings
- 66
Breakdown
Holdings (66)
| Name | Ticker | Weight |
|---|---|---|
| Moderna Inc | MRNA | 6.11% |
| Iovance Biotherapeutics Inc | IOVA | 4.65% |
| Verastem Inc | VSTM | 2.90% |
| Omeros Corp | OMER | 2.78% |
| Halozyme Therapeutics Inc | HALO | 2.26% |
| Precigen Inc | PGEN | 2.09% |
| Kiniksa Pharmaceuticals International Plc | KNSA | 1.99% |
| Xeris Biopharma Holdings Inc | XERS | 1.91% |
| Novavax Inc | NVAX | 1.86% |
| Rigel Pharmaceuticals Inc | RIGL | 1.86% |
| and 53 more | ||
Similar ETFs
- State Street SPDR S&P Biotech ETFXBI · Overlap 48% · Expense ratio 0.35%
- Invesco Nasdaq Biotechnology ETFIBBQ · Overlap 38% · Expense ratio 0.19%
- iShares Biotechnology ETFIBB · Overlap 38% · Expense ratio 0.44%
- Invesco Biotechnology & Genome ETFPBE · Overlap 32% · Expense ratio 0.59%
- Invesco NASDAQ Biotech UCITS ETFSBIO.L · Overlap 38% · Expense ratio 0.40%
- iShares Nasdaq US Biotechnology UCITS ETFBTEC.L · Overlap 38% · Expense ratio 0.35%
- MiraeAsset TIGER NASDAQ BIO ETF203780.KS · Overlap 38% · Expense ratio 0.30%
Overlap is the share of assets the two funds hold in common.
Historical returns do not guarantee future returns. This is not investment advice.
- Expense ratio
- 0.34%
- Fund assets
- 132.14M USD (all share classes)
- Issuer
- Virtus
- Inception date
- Dec 16, 2014
- Number of holdings
- 66
| Name | Ticker | Weight |
|---|---|---|
| Moderna Inc | MRNA | 6.11% |
| Iovance Biotherapeutics Inc | IOVA | 4.65% |
| Verastem Inc | VSTM | 2.90% |
| Omeros Corp | OMER | 2.78% |
| Halozyme Therapeutics Inc | HALO | 2.26% |
| Precigen Inc | PGEN | 2.09% |
| Kiniksa Pharmaceuticals International Plc | KNSA | 1.99% |
| Xeris Biopharma Holdings Inc | XERS | 1.91% |
| Novavax Inc | NVAX | 1.86% |
| Rigel Pharmaceuticals Inc | RIGL | 1.86% |
| and 53 more | ||
The Virtus Biotech ETF seeks to replicate the overall financial performance, encompassing both price appreciation and income generation, of the LifeSci Biotechnology Products Index, prior to any deductions for fees and expenses. This index specifically comprises biotechnology companies that have received approval from the FDA for at least one drug therapy. Furthermore, the fund underwent a name change on February 27, transitioning from Virtus LifeSci Biotech Products ETF to its current designation.
- State Street SPDR S&P Biotech ETFXBI · Overlap 48% · Expense ratio 0.35%
- Invesco Nasdaq Biotechnology ETFIBBQ · Overlap 38% · Expense ratio 0.19%
- iShares Biotechnology ETFIBB · Overlap 38% · Expense ratio 0.44%
- Invesco Biotechnology & Genome ETFPBE · Overlap 32% · Expense ratio 0.59%
- Invesco NASDAQ Biotech UCITS ETFSBIO.L · Overlap 38% · Expense ratio 0.40%
- iShares Nasdaq US Biotechnology UCITS ETFBTEC.L · Overlap 38% · Expense ratio 0.35%
- MiraeAsset TIGER NASDAQ BIO ETF203780.KS · Overlap 38% · Expense ratio 0.30%
Overlap is the share of assets the two funds hold in common.
Unlock all ETF data
Sign up for FreeUnlock all ETF data
Sign up for Free